Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IVA | US
0.08
1.32%
Healthcare
Biotechnology
31/03/2024
17/03/2026
6.16
6.08
6.31
6.05
Inventiva S.A. a clinical-stage biopharmaceutical company focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix France.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
50.4%1 month
51.0%3 months
63.2%6 months
89.1%-
-
2.10
-1.15
0.54
-1.34
5.65
-
-98.36M
324.94M
324.94M
-
-1.91K
-
-58.70
-1.64K
14.15
0.46
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.92
Range1M
1.19
Range3M
3.17
Rel. volume
0.23
Price X volume
434.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Bicycle Therapeutics Limited | BCYC | Biotechnology | 5.07 | 349.80M | 0.40% | n/a | 4.89% |
| NextCure Inc | NXTC | Biotechnology | 12.32 | 344.66M | 3.01% | n/a | 7.21% |
| Absci Corporation Common Stock | ABSI | Biotechnology | 3.03 | 344.07M | 21.20% | n/a | 6.02% |
| NRXPW | NRXPW | Biotechnology | 0.0249 | 335.10M | 0.00% | n/a | -46.73% |
| Cerus Corporation | CERS | Biotechnology | 1.8 | 333.53M | 0.00% | n/a | 199.34% |
| Regulus Resources Inc | RGLSF | Biotechnology | 2.65 | 332.55M | n/a | 0.00% | |
| Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.65 | 332.34M | 10.88% | n/a | 13.86% |
| AC Immune SA | ACIU | Biotechnology | 3.32 | 328.48M | 6.07% | n/a | 0.00% |
| Xilio Therapeutics Inc. Common Stock | XLO | Biotechnology | 7.43 | 326.57M | -3.00% | n/a | 25.98% |
| SELLAS Life Sciences Group Inc | SLS | Biotechnology | 5.04 | 324.24M | -5.97% | n/a | 23.76% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 19.99 | 331.98M | 0.60% | 34.27 | 26.82% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.21 | 307.51M | -0.93% | n/a | 174.23% |
| Urban One Inc | UONEK | Broadcasting - Radio | 5.65 | 299.49M | -0.53% | n/a | 268.43% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 6.26 | 282.51M | 0.00% | n/a | 3644.76% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.14 | 247.88M | 0.14% | 13.23 | 0.00% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 14.45 | 161.23M | -2.82% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 8.6 | 138.09M | -0.06% | n/a | 286.96% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.26 | 101.97M | -0.16% | 9.09 | 39.79% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.9 | 100.23M | 0.58% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.16 | 69.88M | -1.24% | 14.48 | 7.10% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.34 | 0.53 | Cheaper |
| Ent. to Revenue | 5.65 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 63.22 | 72.80 | Par |
| Debt to Equity | -1.15 | -1.23 | Cheaper |
| Debt to Assets | 0.54 | 0.25 | Expensive |
| Market Cap | 324.94M | 3.66B | Emerging |